DALLAH HEALTHCARE COMPANY |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 160.8 SAR | -0.37% |
|
-1.11% | -6.40% |
| 03-20 | Dallah Healthcare Company Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 03-14 | Dallah Healthcare Logs Higher FY23 Net Profit, Revenue | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company returns high margins, thereby supporting business profitability.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company is in debt and has limited leeway for investment
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 40.67 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Most analysts recommend that the stock should be sold or reduced.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -6.40% | 4.2B | - | ||
| -15.68% | 16.57B | B+ | ||
| +4.50% | 12.51B | B | ||
| +4.48% | 11.69B | B+ | ||
| +5.56% | 10.36B | B+ | ||
| +26.66% | 8.38B | B | ||
| -2.19% | 7.75B | A- | ||
| +20.39% | 7.12B | D | ||
| +3.42% | 6.6B | B- | ||
| +46.01% | 4.54B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 4004 Stock
- Ratings Dallah Healthcare Company